恒瑞医药SHR-1894注射液临床试验获批

Core Viewpoint - Heng Rui Medicine's subsidiary, Suzhou Shengdiya Biopharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for clinical trials of SHR-1894 injection, a self-developed biological product aimed at treating atopic dermatitis [1] Group 1 - SHR-1894 injection is expected to protect the skin barrier and suppress inflammation during the treatment of atopic dermatitis [1] - Currently, there are no similar drugs approved for market release domestically or internationally [1]